FAS and glioblastoma: The analysis of overall survival in glioma patients from two different cohorts of The Cancer Genome Atlas (TCGA) database demonstrated inferior survival by the trend in patients with higher CD95 mRNA expression levels among isocitrate dehydrogenase (IDH)-mutant gliomas, but not in glioblastoma, IDH wildtype, assessed by setting either median CD95 mRNA expression or the highest association with survival as a cut-off (Fig. S1A, C).